Resources › Case notes

Semaglutide nasal spray: the Dutch pharmacy exemption does not cover compounding at scale

Published 20 November 2026 · Last reviewed 20 November 2026 · MPA Business Services

On 5 August 2026 the preliminary relief judge of the District Court of The Hague granted Novo Nordisk an injunction against Ceban, a Breda compounding pharmacy that had made a semaglutide nasal spray and supplied it to its own patients and to other pharmacies. The patent law pharmacy exemption covers preparation for direct use, for individual patients, on prescription, and only where there is a medical need the patentee's own product cannot meet. Supplying other pharmacies, listing the product in the G-Standaard and holding active ingredient far beyond any individual need fell outside it, and Ceban had not shown that its own patients could not use the injection or the tablet.

Product
Semaglutide nasal spray compounded by a pharmacy; Novo Nordisk's Ozempic and Wegovy (injection) and Rybelsus (tablet)
Active substance
semaglutide
Originator
Novo Nordisk
Challengers
Ceban Ziekenhuisfarmacie, a compounding pharmacy in Breda
Courts
District Court of The Hague, preliminary relief judge
Decided
5 August 2026 (C/09/704955 / KG ZA 26-494)
Jurisdictions
Netherlands

What was decided

Semaglutide’s compound patent expired in 2026, but in the Netherlands its supplementary protection certificate (SPC) runs until 2031, and while it runs only Novo Nordisk may make, offer, sell, import or stock the substance. Novo Nordisk sells it as a weekly injection (Ozempic, Wegovy) and as a tablet (Rybelsus).

Ceban, a Breda pharmacy at the centre of a group of compounding and supply businesses in the Netherlands, Belgium and Spain, made a semaglutide nasal spray in 2025 without a marketing authorisation. It dispensed the spray, under its own brand name, to its patients and supplied it to other pharmacies for their patients. In November 2025 it had the product listed in the G-Standaard, the Dutch medicines database that pharmacies and prescribing systems draw on. It said the spray was for patients afraid of injections, that 44 sprays had been made, and that the active ingredient came from a supplier in China.

Ceban relied on the Dutch Patents Act’s pharmacy exemption, which takes outside the patent the preparation of medicines in a pharmacy for direct use in individual cases on prescription, and dealings in medicines so prepared. On 5 August 2026 the preliminary relief judge rejected the defence, for these reasons:

  • The exemption is narrow. It is meant for a pharmacist preparing a medicine for an individual patient, for example where no suitable dose or form exists. It does not allow a patented medicine to be made on a structural scale, and it applies only where there is a medical need that the patentee’s own product cannot meet.
  • Supply to other pharmacies, and the listing, were outside it. Both sides accepted this. The court added that listing a product in the G-Standaard is itself an offer for sale.
  • There is no safe number. Ceban’s argument that the exemption allowed preparation for around 50 patients a month had no basis.
  • The signs pointed to scale. Ceban had imported 600 grams of semaglutide, enough on Novo Nordisk’s unchallenged figure for about 15,000 sprays, had given the product a brand name and had listed it nationally. Holding that much active ingredient, far beyond any individual need, was itself an act reserved to the SPC holder.
  • Even its own patients were not shown to need it. Ceban had not shown that each patient was unable to use the injection, or why the tablet would not do. Whether particular past supplies were lawful was left for full proceedings.
  • The regulatory exemption is a different question. Rules that let pharmacies prepare medicines without a marketing authorisation protect patients’ access to medicines; they say nothing about whether a patent or SPC is infringed.

The court ordered Ceban to stop infringing the SPC in the Netherlands, in particular to stop supplying other pharmacies, and to remove the spray from the G-Standaard, from GP prescribing systems and from its website. It must recall what it supplied to other pharmacies, and within four weeks disclose its professional customers, its supplier of semaglutide with quantities and dates, and how many sprays it made and stocked. Penalties run to €500,000, and Ceban pays €50,053.77 in costs. A claim over a presentation a Ceban employee gave at a compounding congress in Portugal failed: talking about a formulation is not offering it.

Timeline

Date Event
2025 Ceban starts making and supplying the semaglutide nasal spray
November 2025 The spray is listed in the G-Standaard
December 2025 – April 2026 Novo Nordisk objects, asks the health inspectorate to act and sends a patent demand; Ceban pauses supply to other pharmacies
2026 Semaglutide’s compound patent expires; the Dutch SPC continues to 2031
1 July 2026 Hearing
5 August 2026 Injunction, recall and disclosure ordered

What it means if you are…

A wholesaler or parallel trader. A pharmacy preparation of a protected molecule is not a lawful alternative supply. Offering, stocking or passing on such a product while the SPC runs can itself infringe, and the court treated the national listing as an offer. The exemption covers the preparing pharmacy’s own individual patients and nothing beyond.

A compounding or hospital pharmacy. The test is need, not volume. Preparing a protected medicine in a different form is defensible only patient by patient, on prescription, where the authorised product will not do, and the pharmacy should be able to show why for each patient. Listing, branding, supplying colleagues and buying active ingredient in bulk all point the other way.

A generics or launch planner. The case confirms that the protection that matters for semaglutide in Europe now is the SPC, not the compound patent, and that it runs to 2031 in the Netherlands. The compound patent’s expiry opened nothing.

A buyer or procurement team. Unauthorised versions of high-demand medicines carry patent risk as well as regulatory risk, and a regulator’s tolerance of pharmacy preparation does not remove the first.

The same exemption elsewhere

The wording is close to identical across Europe, because it comes from the same source. The UPC Agreement (Article 27(e)), the German Patent Act (section 11 no. 3) and the UK Patents Act (section 60(5)(c)) all exempt the extemporaneous preparation of a medicine in a pharmacy for an individual patient on prescription, and dealings in a medicine so prepared. In the Netherlands the provision was written into the law in 1987 but brought into force only on 1 February 2019. This is one of the first decisions to say how far it reaches, and it reads it narrowly.

Status and what to watch

Whether Ceban appeals or brings full proceedings, which it must do within six months; the Dutch health inspectorate’s decision on Novo Nordisk’s separate enforcement request; and whether courts elsewhere read their own pharmacy exemptions the same way as compounded versions of semaglutide and other protected medicines appear in more markets.

Sources

This note is general information, not legal advice. The position for any particular product and country must be checked against the registers; that is what MPA Search is for.

The position in every country, kept current

MPA Search holds the patent, SPC, licence and price position for products across the UK and Europe, with the reference to the original record. Book a free demonstration.